Alphabet's Verily Gains FDA Approval for Study Watch ECG Feature
Verily, Alphabet's life sciences arm, receives FDA clearance for an on-demand ECG feature on its clinical Study Watch. This milestone hints at potential health-tracking capabilities for future Google consumer wearables.
Alphabet's healthcare division Verily earns FDA clearance for its electrocardiogram (ECG) technology integrated into the Study Watch. This medical-grade device features an E Ink display and functions as a prescription-only tool designed specifically to gather vital signs for serious clinical research on conditions like Parkinson's and multiple sclerosis.
The new on-demand, single-lead ECG capability allows the watch to support both large-scale population research and individual clinical care. Verily emphasizes that this regulatory approval demonstrates a strong commitment to FDA safety and effectiveness standards, paving the way for expanded use of the Study Watch across various disease areas.
This FDA clearance arrives shortly after Google announces a $40 million deal to acquire Fossil's wearable technology, sparking speculation about health features in a potential upcoming Pixel Watch. Following Apple's successful integration of ECG into the Apple Watch, this regulatory win provides Google with a proven foundation to bring similar advanced health-tracking capabilities to its own future consumer devices.